DUBLIN--(BUSINESS WIRE)--The "Metabolic Disorders Drugs Global Market Report 2019" report has been added to ResearchAndMarkets.com's offering.
Global Metabolic Disorders Drugs Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs market.
Where is the largest and fastest growing market for the metabolic disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Metabolic Disorders Drugs market global report answers all these questions and many more.
The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases.
This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders.
North America was the largest region in the global metabolic disorders drugs market, accounting for 42% of the market in 2018. Western Europe was the second largest region accounting for 24% of the global metabolic disorders drugs market. Africa was the smallest region in the global metabolic disorders drugs market.
Administration (FDA) has approved various enzyme replacement therapies for the treatment of metabolic disorders. Enzyme replacement therapy is used for treatment of rare genetic disorders through purified human, animal or recombinant enzymes. In December 2015, the FDA approved an enzyme replacement therapy Kanuma that can be used to treat adult and pediatric patients suffering from lysosomal acid lipase deficiency, a metabolic disorder that causes problems with the breakdown and use of fats and cholesterol in the body.
Similarly, in October 2015, FDA had announced the approval of Strensiq, a drug that can be used for the treatment of perinatal, infantile and juvenile-onset hypophosphatasia, which is a metabolic disorder affecting multiple body systems.
Key Topics Covered:
1. Executive Summary
2. Report Structure
3. Metabolic Disorders Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Metabolic Disorders Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Metabolic Disorders Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Metabolic Disorders Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Metabolic Disorders Drugs Market Trends And Strategies
8. Metabolic Disorders Drugs Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, Value ($ Billion)
8.2.1. Drivers Of The Market
8.2.2. Restraints On The Market
8.3. Forecast Market Growth, Value ($ Billion)
8.3.1. Drivers Of The Market
8.3.2. Restraints On The Market
9. Metabolic Disorders Drugs Market Regional Analysis
9.1. Global Metabolic Disorders Drugs Market, 2018, By Region, Value ($ Billion)
9.2. Global Metabolic Disorders Drugs Market, 2014 - 2022, Historic And Forecast, By Region
9.3. Global Metabolic Disorders Drugs Market, Growth And Market Share Comparison, By Region
10. Metabolic Disorders Drugs Market Segmentation
10.1. Global Metabolic Disorders Drugs Market, Segmentation By Type, 2014 - 2022, Value ($ Billion)
10.1.1. Anti Diabetics drugs
10.1.2. Anti-Thyroid drugs
10.1.3. Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11. Metabolic Disorders Drugs Market Metrics
11.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, 2014 - 2022, Global
11.2. Per Capita Average Metabolic Disorders Drugs Market Expenditure, 2014 - 2022, Global
Companies Mentioned
- Sanofi S.A
- Novo Nordisk A/S
- AstraZeneca Plc
- Johnson & Johnson
- Merck & Co
For more information about this report visit https://www.researchandmarkets.com/r/285owz
